Sobi Q3 2024 report: Strong growth and significant pipeline momentum
Third Quarter 2024
- Total revenue increased 33 per cent, 39 per cent at constant exchange rates, (CER)1, to
SEK 6,894 M (5,168) - Haematology revenue increased 18 per cent at CER to
SEK 4,000 M (3,484), mainly driven by strong sales of Doptelet® ofSEK 1,039 M (650), sales of Aspaveli®/Empaveli® ofSEK 270 M (169) and launch sales of Altuvoct® ofSEK 129 M (—) - Immunology revenue increased 96 per cent at CER to
SEK 2,583 M (1,400), driven by strong Beyfortus® royalty ofSEK 1,478 M (263) and sales of Kineret® ofSEK 699 M (600) - Revenue from medicines in the strategic portfolio* grew by 113 per cent at CER to
SEK 3,830 M (1,924) - The adjusted EBITA margin1,2 was 43 per
cent (30) , excluding items affecting comparability (IAC)2. EBITA wasSEK 2,923 M (1,443), corresponding to a margin of 42 percent (28) . EBIT wasSEK 2,038 M (547) - Earnings per share (EPS) before dilution was
SEK 4.27 (0.30). Adjusted EPS before dilution1 wasSEK 4.36 (0.54). Cash flow from operating activities wasSEK 1,201 M (1,058) - In August,
Sobi and Apellis Pharmaceuticals announced positive topline results from the Phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN
Outlook 2024 - Updated
- Revenue is anticipated to grow by a mid-teens percentage at CER (previously low double-digit)
- The adjusted EBITA margin is anticipated to be in the mid-30s percentage of revenue (unchanged)
Click here for the Financial Summary.
- Alternative Performance Measures (APMs).
- Items affecting comparability (IAC).
* The strategic portfolio includes Sobi's medicines Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant®, Vonjo® and Zynlonta®, and royalty on Sanofi's sales of Altuviiio® and Beyfortus.
Investors, analysts, and the media are invited to a conference call on the same day at 14:00 CEST,
The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call.
To participate in the conference call, please use the following dial-in details:
For other countries, please find the details here.
Sobi
Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:00 CEST on
Head of Investor Relations
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Q3 2024 report. Strong growth and significant pipeline momentum |
View original content:https://www.prnewswire.co.uk/news-releases/sobi-q3-2024-report-strong-growth-and-significant-pipeline-momentum-302285671.html